The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs

Metabolism: Clinical and Experimental
H R DavisR W Watkins

Abstract

Ezetimibe (SCH 58235) and SCH 48461 are potent cholesterol absorption inhibitors, which cause significant decreases in plasma cholesterol levels in cholesterol-fed animals and in humans with hypercholesterolemia. These compounds selectively block intestinal uptake and absorption of cholesterol. These cholesterol absorption inhibitors cause modest, inconsistent reductions in plasma cholesterol levels in animals fed cholesterol-free chow diets. Although, these compounds block cholesterol absorption and increase neutral sterol excretion, chow-fed animals compensate for the loss of biliary cholesterol by increasing hepatic cholesterol synthesis. Therefore, we determined the effect of SCH 48461 and ezetimibe in combination with 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors in chow-fed dogs. A synergistic reduction in plasma cholesterol was observed in chow-fed dogs given SCH 48461 (0.1 mg/kg/d) and the HMG CoA reductase inhibitor, lovastatin (5 mg/kg/d). Neither SCH 48461 nor lovastatin alone affected plasma cholesterol levels. Their combination for 14 days caused a 36% reduction in plasma cholesterol levels from 129 mg/dL to 83 mg/dL (P <.05). Ezetimibe (0.007 mg/kg/d) also caused synergistic reductions in pl...Continue Reading

Citations

Sep 19, 2002·British Journal of Clinical Pharmacology·Teddy KosoglouMelton B Affrime
Jul 24, 2010·American Journal of Physiology. Gastrointestinal and Liver Physiology·Li YangPatrick Tso
Jan 26, 2011·Journal of Lipid Research·Brandon AsonNelly A Kuklin
Mar 24, 2009·Journal of Lipid Research·André J TremblayPatrick Couture
Aug 23, 2012·Vascular Health and Risk Management·Binh An P PhanPeter P Toth
Sep 3, 2010·Annual Review of Physiology·Lin JiaLiqing Yu
Oct 31, 2003·Expert Opinion on Investigational Drugs·Pedro Iglesias, Juan J Díez
Dec 9, 2009·Expert Opinion on Drug Safety·Fabrizio MontecuccoFrançois Mach
Nov 20, 2002·Expert Opinion on Investigational Drugs·Harold Bays
Aug 9, 2005·Current Medical Research and Opinion·Larisa ReydermanPaul Statkevich
May 30, 2003·The Annals of Pharmacotherapy·Vincent F Mauro, Chad E Tuckerman
Nov 30, 2006·Journal of Lipid Research·Dawn E TelfordMurray W Huff
Oct 9, 2002·Circulation·Thomas SudhopKlaus von Bergmann
Mar 11, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·André J TremblayPatrick Couture
Jan 16, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Harry R DavisScott W Altmann
Dec 18, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·H R DavisG Tetzloff
Aug 7, 2002·Current Atherosclerosis Reports·Margaret E Brousseau, Ernst J Schaefer
May 7, 2005·International Journal of Clinical Practice. Supplement·E DohertyA S Wierzbicki
Dec 4, 2009·International Journal of Cancer. Journal International Du Cancer·Erin McNamara, Michael C Archer
Jun 21, 2005·International Journal of Clinical Practice·Harold Bays, Thomas Musliner
Dec 15, 2005·International Journal of Clinical Practice·J J P Kastelein, R R Sankatsing
Feb 9, 2012·British Journal of Clinical Pharmacology·Inge De MeyerGuido R Y De Meyer
Oct 9, 2016·Journal of Pediatric Endocrinology & Metabolism : JPEM·María Beatriz Araujo, María Sol Pacce
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Malcolm J M DarkesKaren L Goa
Jul 4, 2003·Current Opinion in Lipidology·Stephen D Turley, John M Dietschy
Dec 4, 2003·Cardiovascular Drug Reviews·Leslie J Lipka
Apr 9, 2010·Southern Medical Journal·Nurver TurfanerHabibe Genc
Nov 28, 2017·Food & Function·Alicia Gil-RamírezCristina Soler-Rivas
Oct 31, 2006·World Journal of Gastroenterology : WJG·Janine-K KruitFolkert Kuipers
Sep 30, 2008·International Journal of Clinical Practice·A S Wierzbicki
Oct 13, 2006·Current Opinion in Gastroenterology·Richard E Ostlund
Jun 15, 2006·The Journal of Nutrition·François BriandPatrick Nguyen
Dec 30, 2003·Journal of Medicinal Chemistry·John W Clader
Apr 1, 2004·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G D Norata, A L Catapano

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.